arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Eledon Pharmaceuticals, Inc.

ELDN Health Care Biotechnology: Pharmaceutical Preparations
$3.02
Today
as of Sep 4, 16:48 ET
Last 30 days -15.41% Jul 27 → Sep 04
$2.86 $3.11 $3.35 $3.59 $3.84 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$2.97
High
$3.06
Low
$2.93
Volume
$1M
Avg Vol
$1M
Mkt Cap
$286M
P/E (TTM)
—
Beta
—
52w High
$4.60
52w Low
$1.35
Div Yield
—
Shares Out
$81M

Recent Press Releases & News last 60 days · 3 items

Sep 3 · 11:49 MT Newswires
Eledon Pharmaceuticals Submits IND Application to US FDA for Tegoprubart
Sep 3 · 11:00 PR GlobeNewswire
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
Aug 13 · 20:05 PR GlobeNewswire
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Overview

52-week range
$1.35
$4.60
51% of range
Avg surprise (last 3)
+47.4%
Avg reaction (last 2)
-1.5%
0% positive
Latest IV / EM
233%
EM ±36.4% · $3 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.92$-0.71$-0.50$-0.29$-0.08 Actual $-0.75Actual $-0.33Actual $-0.65Actual $-0.92Actual $-0.28Actual $-0.08Est $-0.28Actual $-0.13Est $-0.23Actual $-0.21Actual $-0.16Est $-0.22Actual $-0.27 MarSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-39M$-9M$21M$51M$81M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.27 — — — — financials
Wed May 13, 2026Mar/2026 $-0.16 $-0.22 +27.3% -100.0% -0.5% earnings
Tue Sep 30, 2025Sep 2025 $-0.21 — — — — financials
Thu Aug 14, 2025Jun/2025 $-0.13 $-0.23 +43.5% — — earnings
Wed May 14, 2025Mar/2025 $-0.08 $-0.28 +71.4% — -2.4% earnings
Mon Sep 30, 2024Sep 2024 $-0.28 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.92 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.65 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.33 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.75 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-23M$-21M—$-19M$-25M$-18M—$-21M
Net income$-32M$-39M—$-17M$-11M$-6M—$77M
EPS (diluted)$-0.27$-0.33—$-0.21$-0.13$-0.08—$-0.28

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$7M$6M$23M$4M$6M$8M$21M$7M
Inventory————————
Total current assets$93M$114M$136M$96M$111M$128M$144M$82M
Total assets$126M$147M$169M$130M$145M$161M$177M$115M
Long-term debt————————
Total liabilities$54M$46M$32M$39M$39M$47M$59M$39M
Total equity$33M$45M$81M$35M$50M$59M$62M$20M

Implied volatility — last 90 days

141%494%847%1200%1553% Jun 07 — IV 466% · EM ±64.5%Jun 08 — IV 447% · EM ±59.0%Jun 09 — IV 540% · EM ±67.6%Jun 10 — IV 514% · EM ±60.7%Jun 11 — IV 583% · EM ±64.4%Jun 12 — IV 657% · EM ±67.2%Jun 15 — IV 826% · EM ±59.8%Jun 16 — IV 900% · EM ±53.2%Jun 17 — IV 1553% · EM ±64.9%Jun 19 — IV 251% · EM ±55.5%Jun 22 — IV 186% · EM ±38.9%Jun 23 — IV 180% · EM ±36.7%Jun 24 — IV 211% · EM ±42.3%Jun 25 — IV 173% · EM ±33.9%Jun 26 — IV 359% · EM ±68.8%Jun 29 — IV 379% · EM ±67.2%Jun 30 — IV 331% · EM ±57.0%Jul 01 — IV 211% · EM ±35.3%Jul 02 — IV 219% · EM ±35.4%Jul 03 — IV 227% · EM ±35.4%Jul 06 — IV 400% · EM ±55.4%Jul 07 — IV 284% · EM ±37.5%Jul 08 — IV 421% · EM ±52.8%Jul 09 — IV 420% · EM ±49.6%Jul 10 — IV 525% · EM ±58.0%Jul 13 — IV 713% · EM ±59.6%Jul 14 — IV 870% · EM ±63.0%Jul 15 — IV 964% · EM ±56.9%Jul 16 — IV 1434% · EM ±59.9%Jul 20 — IV 241% · EM ±57.0%Jul 21 — IV 142% · EM ±32.9%Jul 22 — IV 322% · EM ±73.7%Jul 23 — IV 333% · EM ±74.9%Jul 24 — IV 289% · EM ±63.9%Jul 27 — IV 302% · EM ±63.0%Jul 28 — IV 331% · EM ±67.6%Jul 29 — IV 302% · EM ±60.4%Jul 30 — IV 282% · EM ±55.2%Jul 31 — IV 278% · EM ±53.3%Aug 03 — IV 304% · EM ±53.9%Aug 04 — IV 301% · EM ±51.9%Aug 05 — IV 244% · EM ±40.7%Aug 06 — IV 286% · EM ±46.2%Aug 07 — IV 393% · EM ±61.5%Aug 10 — IV 402% · EM ±55.7%Aug 11 — IV 414% · EM ±54.7%Aug 12 — IV 531% · EM ±66.6%Aug 13 — IV 573% · EM ±67.7%Aug 14 — IV 447% · EM ±49.4%Aug 17 — IV 717% · EM ±59.9%Aug 18 — IV 745% · EM ±53.9%Aug 19 — IV 930% · EM ±54.9%Aug 20 — IV 1326% · EM ±55.4%Aug 24 — IV 295% · EM ±61.6%Aug 25 — IV 310% · EM ±63.4%Aug 26 — IV 291% · EM ±58.2%Aug 27 — IV 277% · EM ±54.2%Aug 28 — IV 278% · EM ±53.1%Aug 31 — IV 265% · EM ±47.0%Sep 02 — IV 210% · EM ±35.1%Sep 03 — IV 222% · EM ±35.8%Sep 04 — IV 233% · EM ±36.4%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in